PMID- 29325770
OWN - NLM
STAT- MEDLINE
DCOM- 20180903
LR  - 20181202
IS  - 1873-3441 (Electronic)
IS  - 0939-6411 (Linking)
VI  - 125
DP  - 2018 Apr
TI  - Development of a non-toxic and non-denaturing formulation process for 
      encapsulation of SDF-1alpha into PLGA/PEG-PLGA nanoparticles to achieve sustained 
      release.
PG  - 38-50
LID - S0939-6411(17)31295-X [pii]
LID - 10.1016/j.ejpb.2017.12.020 [doi]
AB  - Chemokines are known to stimulate directed migration of cancer cells. Therefore, 
      the strategy involving gradual chemokine release from polymeric vehicles for 
      trapping cancer cells is of interest. In this work, the chemokine stromal 
      cell-derived factor-1alpha (SDF-1alpha) was encapsulated into nanoparticles composed of 
      poly-(lactic-co-glycolic acid) (PLGA) and a polyethylene glycol (PEG)-PLGA 
      co-polymer to achieve sustained release. SDF-1alpha, and lysozyme as a model protein, 
      were firstly precipitated to promote their stability upon encapsulation. A novel 
      phase separation method utilising a non-toxic solvent in the form of isosorbide 
      dimethyl ether was developed for the individual encapsulation of SDF-1alpha and 
      lysozyme precipitates. Uniform nanoparticles of 200-250 nm in size with spherical 
      morphologies were successfully synthesised under mild formulation conditions and 
      conveniently freeze-dried in the presence of hydroxypropyl-beta-cyclodextrin as a 
      stabiliser. The effect of PLGA carboxylic acid terminal capping on protein 
      encapsulation efficiency and release rate was also explored. Following 
      optimisation, sustained release of SDF-1alpha was achieved over a period of 72 h. 
      Importantly, the novel encapsulation process was found to induce negligible 
      protein denaturation. The obtained SDF-1alpha nanocarriers may be subsequently 
      incorporated within a hydrogel or other scaffolds to establish a chemokine 
      concentration gradient for the trapping of glioblastoma cells.
CI  - Copyright (c) 2017 Elsevier B.V. All rights reserved.
FAU - Haji Mansor, Muhammad
AU  - Haji Mansor M
AD  - CRCINA, INSERM, Universite de Nantes, Universite d'Angers, Angers, France; Center 
      for Education and Research on Macromolecules (CERM), Universite de Liege, Liege, 
      Belgium.
FAU - Najberg, Mathie
AU  - Najberg M
AD  - CRCINA, INSERM, Universite de Nantes, Universite d'Angers, Angers, France; 
      Departamento de Farmacologia, Farmacia y Tecnologia Farmaceutica, R & D Pharma 
      Group, Facultad de Farmacia, Universidade de Santiago de Compostela, Santiago de 
      Compostela, Spain.
FAU - Contini, Aurelien
AU  - Contini A
AD  - CRCINA, INSERM, Universite de Nantes, Universite d'Angers, Angers, France.
FAU - Alvarez-Lorenzo, Carmen
AU  - Alvarez-Lorenzo C
AD  - Departamento de Farmacologia, Farmacia y Tecnologia Farmaceutica, R & D Pharma 
      Group, Facultad de Farmacia, Universidade de Santiago de Compostela, Santiago de 
      Compostela, Spain.
FAU - Garcion, Emmanuel
AU  - Garcion E
AD  - CRCINA, INSERM, Universite de Nantes, Universite d'Angers, Angers, France.
FAU - Jerome, Christine
AU  - Jerome C
AD  - Center for Education and Research on Macromolecules (CERM), Universite de Liege, 
      Liege, Belgium.
FAU - Boury, Frank
AU  - Boury F
AD  - CRCINA, INSERM, Universite de Nantes, Universite d'Angers, Angers, France. 
      Electronic address: frank.boury@univ-angers.fr.
LA  - eng
PT  - Journal Article
DEP - 20180108
PL  - Netherlands
TA  - Eur J Pharm Biopharm
JT  - European journal of pharmaceutics and biopharmaceutics : official journal of 
      Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
JID - 9109778
RN  - 0 (Chemokine CXCL12)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Carriers)
RN  - 0 (poly(lactic-co-glycolic acid)-polyethylene glycol-poly(lactic-co-glycolic 
      acid))
RN  - 34346-01-5 (Polyglactin 910)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - EC 3.2.1.17 (Muramidase)
SB  - IM
MH  - Animals
MH  - Chemokine CXCL12/administration & dosage/chemistry/*pharmacokinetics
MH  - Delayed-Action Preparations/administration & dosage/chemistry/pharmacokinetics
MH  - Dose-Response Relationship, Drug
MH  - Drug Carriers/administration & dosage/chemistry/*pharmacokinetics
MH  - Drug Compounding
MH  - *Drug Liberation
MH  - Mice
MH  - Muramidase/administration & dosage/chemistry/pharmacokinetics
MH  - NIH 3T3 Cells
MH  - Nanoparticles/administration & dosage/chemistry/*metabolism
MH  - Polyethylene Glycols/administration & dosage/chemistry/*pharmacokinetics
MH  - Polyglactin 910/administration & dosage/chemistry/*pharmacokinetics
OTO - NOTNLM
OT  - Polymeric nanoparticles
OT  - Protein encapsulation
OT  - Stromal cell-derived factor-1alpha (SDF-1alpha)
OT  - Sustained release
EDAT- 2018/01/13 06:00
MHDA- 2018/09/04 06:00
CRDT- 2018/01/13 06:00
PHST- 2017/11/10 00:00 [received]
PHST- 2017/12/12 00:00 [revised]
PHST- 2017/12/29 00:00 [accepted]
PHST- 2018/01/13 06:00 [pubmed]
PHST- 2018/09/04 06:00 [medline]
PHST- 2018/01/13 06:00 [entrez]
AID - S0939-6411(17)31295-X [pii]
AID - 10.1016/j.ejpb.2017.12.020 [doi]
PST - ppublish
SO  - Eur J Pharm Biopharm. 2018 Apr;125:38-50. doi: 10.1016/j.ejpb.2017.12.020. Epub 
      2018 Jan 8.